Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clopidogrel
Drug ID BADD_D00504
Description Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Indications and Usage Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Marketing Status approved
ATC Code B01AC04
DrugBank ID DB00758
KEGG ID D07729; D10823; D10824
MeSH ID D000077144
PubChem ID 60606
TTD Drug ID D0N0TZ
NDC Product Code 42543-714; 50090-4918; 52605-083; 16729-218; 0024-1171; 68788-8190; 72578-012; 65977-0037; 52605-082; 63187-362; 63629-4728; 70518-0400; 33342-060; 42543-713; 65162-414; 0093-7314; 16729-219; 61919-007; 67296-1840; 50090-2598; 50090-5781; 0024-1332; 61919-737; 70771-1062; 16714-052; 68071-2813; 68071-4138; 71335-0581
UNII A74586SNO7
Synonyms Clopidogrel | SC 25989C | SC 25990C | SR 25989 | Clopidogrel-Mepha | Clopidogrel Mepha | Clopidogrel Sandoz | Iscover | Clopidogrel Napadisilate | Clopidogrel Hydrochloride | PCR 4099 | PCR-4099 | Clopidogrel Besylate | Clopidogrel Besilate | Clopidogrel, (+)(S)-isomer | Plavix | Clopidogrel Bisulfate
Chemical Information
Molecular Formula C16H16ClNO2S
CAS Registry Number 113665-84-2
SMILES COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tumour rupture16.32.03.0330.000021%Not Available
Lip pruritus07.05.05.0210.000032%Not Available
Psychological trauma19.01.02.0170.000064%Not Available
Gastrointestinal polyp haemorrhage16.05.01.008; 24.07.02.046; 07.20.01.0110.000053%Not Available
Spontaneous haemorrhage24.07.01.081; 01.01.03.0070.000032%Not Available
Internal haemorrhage24.07.01.0720.000075%Not Available
Thunderclap headache17.14.01.0180.000021%Not Available
Disorganised speech17.02.08.017; 19.19.02.0050.000021%Not Available
Chest wall haematoma24.07.01.065; 15.03.05.0050.000032%Not Available
Lacunar stroke24.04.06.037; 17.08.01.0540.000021%Not Available
Vascular stent occlusion24.04.02.026; 08.07.05.0050.000032%Not Available
Vascular stent stenosis24.04.02.028; 08.07.05.0070.000064%Not Available
Hyperinsulinaemic hypoglycaemia14.06.03.010; 05.06.03.0100.000032%Not Available
Oesophageal intramural haematoma24.07.02.050; 07.12.01.0060.000032%Not Available
Intracranial mass17.11.01.0170.000086%Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000021%Not Available
Atheroembolism24.01.01.037; 12.02.05.0520.000032%Not Available
Biliary obstruction09.02.02.0050.000043%Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.000289%Not Available
Brown-Sequard syndrome17.10.01.025; 12.01.13.0090.000032%Not Available
Catheter site haematoma24.07.01.090; 12.07.02.020; 08.02.02.0200.000032%Not Available
Cerebral mass effect17.11.01.0190.000043%Not Available
Chronic gastrointestinal bleeding24.07.02.062; 07.12.02.009--Not Available
Cross sensitivity reaction10.01.01.036--Not Available
Eosinophilic pleural effusion22.05.02.009; 01.02.04.0230.000021%Not Available
Eye haematoma24.07.05.017; 12.01.04.034; 06.07.02.0090.000032%Not Available
Femoral artery aneurysm24.02.05.0020.000021%Not Available
Fixed eruption10.01.01.037; 08.01.06.025; 23.03.05.0080.000064%Not Available
Gastrointestinal angiectasia24.03.03.048; 07.15.04.0090.000021%Not Available
Gastrointestinal vascular malformation haemorrhagic24.07.02.064; 07.15.04.0100.000053%Not Available
The 26th Page    First    Pre   26 27    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene